Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?
Dr. John Cush RheumNow
4 years ago
Multinatinal cross-sectional survey of 2270 PsA pts shows despite comparable Dz duration, presentation, biologic use (54%), Women had worse QOL, more disability and work activity impairment (but less comorbidities) https://t.co/1KbDuxaMFf https://t.co/SsbSHQNsPV
Dr. John Cush RheumNow
4 years ago
BIOBADASER registry study of 969 axSpA pts (315 females, 654 males; 2000-2019) who initiated a TNFi shows nonresponse (BASDAI50) was more likely in women (p=0.018), older age at the start of TNFi therapy. https://t.co/Zp7PWhEMav https://t.co/1XY0dC0QCW
The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.
Dr. John Cush RheumNow
4 years ago
Single center study from UAB shows 72 gout pts treated & D/C from ED were Rx w/ steroids (64%), opioids (63%), NSAIDs (43%), colchicine (32%). But only 26/72 (36%) had subsequent outpatient clinic visit for gout. https://t.co/I8jjqIqJXd https://t.co/05YSibd6iz
Dr. John Cush RheumNow
4 years ago
JAK inhibitor labeling in Canada updated to include risks of MACE, fatal VTE and cancer for tofacitinib (Xeljanz) (also applied to Cibinqo, Inrebic, Jakavi, Olumiant, Rinvoq Xeljanz) https://t.co/FEbHE4wN3I https://t.co/EN80i9cY5h
Dr. John Cush RheumNow
4 years ago
Dr. Chao will be covering PsA and AS for the RheumNow team at #ACR22.
“I’m looking forward to the exciting hybrid format of both in person and virtual meeting this year!”
Follow @doctorRBC for real-time #ACR22 coverage. https://t.co/3sbBhVPPZ2
Treat-to-target management of SLE has been shown to protect against organ damage and to improve quality of life. Now a prospective study shows that T2T with a goal of lupus low disease activity state and remission has been shown to improve mortality risk.
The CDC has updated its Guideline for Prescribing Opioids for Chronic Pain and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1–3 months), and chronic (duration of >3 months) pain.
Dr. John Cush RheumNow
4 years ago
Introducing Dr. Akhil Sood, who will be covering #ACR22 on behalf of RheumNow.
He is excited to learn more about the cutting-edge research in the field of Rheumatology & Immunology.
Follow him @AkhilSoodMD for real-time coverage! https://t.co/hXw2CMrwKF
Renaud Felten DocFelten
4 years ago
🆕Recommendation provided by Pharmacovigilance Risk Assessment Committee (#PRAC) about Janus kinase inhibitors #JAKi
⏩EMA recommends measures to minimise risk of serious side effects with #JAKi for chronic inflammatory disorders.
https://t.co/YqaX7UxtUA https://t.co/dCJbqanAxF
Catherine Sims, MD DrCassySims
4 years ago
Think about checking Ig levels prior to Rituximab administration. Low IgM was most common after RTX in RA. The following are risk factors for hypogammaglobulinemia:
🧪 Older age
🧪 Use of steroids
🧪 Repeated doses of RTX
🧪 Low Ig at baseline https://t.co/oOjqnmFdYt
Dr. John Cush RheumNow
4 years ago
RheumNow #ACR22 reporter, Dr. Bella Mehta, will be covering SLE, gout and auto inflammatory topics this year.
“I am looking forward to meeting collegues at ACR after 2 years!” -Dr. Mehta
Follow @bella_mehta for real-time coverage during #ACR22. https://t.co/QQM2NrObPR
The American College of Rheumatology (ACR) has released Continuing Medical Education (CME) for dermatologists and nephrologists to help them learn more about clinical trials for lupus patients in their respective treatment areas and the importance of getting more of their African American/Black patients enrolled.
Dr. John Cush RheumNow
4 years ago
Follow our newest #ACR22 reporter, Dr. Julian Segan ( @JulianSegan)!
“I am looking forward to is meeting all my rheumatology Twitter heroes!”
Follow @RheumNow and our reporters for real-time #ACR22 coverage. https://t.co/7axxfOV6W8
